Mechanism-based inactivation of VanX, a D-alanyl-D-alanine dipeptidase necessary for vancomycin resistance.
VanX is a zinc-dependent D-Ala-D-Ala amino dipeptidase required for high-level resistance to vancomycin. The enzyme is also able to process dipeptides with bulky C-terminal amino acids [Wu, Z., Wright, G. D., and Walsh, C. T. (1995) Biochemistry 34, 2455-2463]. We took advantage of this observation to design and synthesize the dipeptide-like D-Ala-D-Gly(SPhip-CHF(2))-OH (7) as a potential mechanism-based inhibitor. VanX-mediated peptide cleavage generates a highly reactive 4-thioquinone fluoromethide which is able to covalently react with enzyme nucleophilic residues, resulting in irreversible inhibition. Inhibition of VanX by 7 was time-dependent (K(irr) = 30+/-1 microM; k(inact) = 7.3+/- 0.3 min(-1)) and active site-directed, as deduced from substrate protection experiments. Nucleophilic compounds such as sodium azide, potassium cyanide, and glutathione did not protect the enzyme from inhibition, indicating that the generated nucleophile inactivates VanX before leaving the active site. The failure to reactivate the dead enzyme by gel filtration or pH modification confirmed the covalent nature of the reaction that leads to inactivation. Inactivation was associated with the elimination of fluoride ion as deduced from (19)F NMR spectroscopy analysis and with the production of fluorinated thiophenol dimer 12. These data are consistent with suicide inactivation of VanX by dipeptide 7. The small size of the VanX active site and the presence of a number of nucleophilic side chains at the opening of the active site gorge [Bussiere, D. E., et al. (1998) Mol. Cell 2, 75-84] associated with the high observed partition ratio of 7500+/-500 suggest that the inhibitor is likely to react at the entrance of the active site cavity.
Aráoz
R
R
Institut de Chimie des Substances Naturelles, CNRS-UPR2301, 91198 Gif-sur-Yvette, and Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France.
Anhalt
E
E
René
L
L
Badet-Denisot
M A
MA
Courvalin
P
P
Badet
B
B
D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D011232:Chemical Precipitation; D004150:Dipeptidases / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D004151:Dipeptides / Q000138:chemical synthesis / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry; D004793:Enzyme Reactivators / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D011190:Potassium Cyanide / Q000737:chemistry; D046929:Serine-Type D-Ala-D-Ala Carboxypeptidase; D019810:Sodium Azide / Q000737:chemistry; D013056:Spectrophotometry, Ultraviolet; D013379:Substrate Specificity; D017186:Titrimetry; D020713:Vancomycin Resistance
D001426:Bacterial Proteins; D004151:Dipeptides; D004791:Enzyme Inhibitors; D004793:Enzyme Reactivators; C419791:alanyl-glycyl-Spsi(p-CHF2); C002956:alanylalanine; D019810:Sodium Azide; D004150:Dipeptidases; D046929:Serine-Type D-Ala-D-Ala Carboxypeptidase; C091956:VanX dipeptidase; D011190:Potassium Cyanide